Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn [Yahoo! Finance]
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule [Yahoo! Finance]
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule